Satsuma Pharmaceuticals, Inc.

STSACIK 0001692830 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 28, 2023. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0001

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Satsuma Pharmaceuticals, Inc.

Name	Roles	Filings
Harsch Mutya	Director	2
King Thomas Braxton	Director	2
Kolchinsky Peter	Director10% Owner	2
Kollins John A	OfficerDirector	2
Lukatch Heath	Director	2

Showing 1-5 of 15

Per pagePage 1 of 3Next

All filings

23 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Jun 8, 2023	Kollins John A President and CEO · Director	UTender	305,911	$0.91	$278,379
Jun 8, 2023	Soloway Thomas P Director	Holdings only	-	-	-
Jun 8, 2023	Sandoval Elisabeth Director	Holdings only	-	-	-
Jun 8, 2023	Riebe Michael T Director	Holdings only	-	-	-
Jun 8, 2023	Takanashi Ken Director · 10% Owner	PPurchase	22,053,581	$0.91	$20,068,759

Showing 6-10 of 23

Per pagePrevPage 2 of 5Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value